Ashton, Nicholas J.
Hye, Abdul
Rajkumar, Anto P.
Leuzy, Antoine
Snowden, Stuart
Suárez-Calvet, Marc http://orcid.org/0000-0002-2993-569X
Karikari, Thomas K.
Schöll, Michael
La Joie, Renaud http://orcid.org/0000-0003-2581-8100
Rabinovici, Gil D.
Höglund, Kina
Ballard, Clive http://orcid.org/0000-0003-0022-5632
Hortobágyi, Tibor http://orcid.org/0000-0001-5732-7942
Svenningsson, Per
Blennow, Kaj
Zetterberg, Henrik
Aarsland, Dag http://orcid.org/0000-0001-6314-216X
Article History
Accepted: 17 March 2020
First Online: 22 April 2020
Competing interests
: D.A. has received research support and/or honoraria from Astra-Zeneca, GE Health, H. Lundbeck and Novartis Pharmaceuticals, and served as paid consultant for Eisai, H. Lundbeck, Heptares, Mentis Cura and Sanofi. K.B. has served as a consultant or at advisory boards for Alector, Alzheon, Biogen, CogRx, Lilly, Novartis and Roche Diagnostics, all unrelated to the work presented in this paper. H.Z. has participated in scientific advisory boards for CogRx, Roche Diagnostics, Samumed and Wave, has given lectures in symposia sponsored by Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. M.S. has served on an advisory board for Servier. All other authors declare no competing interests.